George Scangos, Ph.D.

George Scangos, Ph.D.

DirectoratVir Biotechnology· In proxies 2021–2025

Pay in FY2023-95% from the year before · Vir Biotechnology stock -60.3% the same year

George Scangos, Ph.D. was paid $338.2K in FY2023 (Dec), down 95%. Vir Biotechnology stock fell 60.3% that year.

Pay$100 in the stock at the end of FY21 → $24
Pay is from the Summary Compensation Table of each Vir Biotechnology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Agilent TechnologiesPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. Vir BiotechnologyPublic company · 5 yr
    • Former President and Chief Executive Officer2021 – Present · 5 yrStock in role -60%
  3. Overseers of UCSFPublic company
    • Director? – PresentNo stock prices for these years
  4. Global Alliance forPublic company
    • Director? – PresentNo stock prices for these years
  5. Global Alliance for TB Drug DevelopmentPublic company · 4 yr
    • Director2006 – 2010 · 4 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?